In:
Science, American Association for the Advancement of Science (AAAS), Vol. 369, No. 6505 ( 2020-08-14), p. 806-811
Abstract:
The global coronavirus disease 2019 (COVID-19) pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top biomedical priority. In this study, we
developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 spike (S) protein and evaluated them in 35 rhesus macaques.
Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers at levels comparable to those found
in convalescent humans and macaques infected with SARS-CoV-2. After vaccination, all animals were challenged with SARS-CoV-2, and the vaccine
encoding the full-length S protein resulted in 〉 3.1 and 〉 3.7
log 10 reductions in median viral loads in
bronchoalveolar lavage and nasal mucosa, respectively, as compared with viral loads in sham controls. Vaccine-elicited neutralizing antibody titers
correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in
nonhuman primates.
Type of Medium:
Online Resource
ISSN:
0036-8075
,
1095-9203
DOI:
10.1126/science.abc6284
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2020
detail.hit.zdb_id:
128410-1
detail.hit.zdb_id:
2066996-3
detail.hit.zdb_id:
2060783-0
SSG:
11
Bookmarklink